Baxter (NYSE:BAX) said yesterday that it has been cleared from a U.S. Dept. of Justice antitrust probe, launched in 2017, investigating companies that market intravenous saline solutions.
The probe came as hospitals endured a shortage of intravenous saline solutions, which are used to hydrate hospital patients. The shortage dates back to late 2013, after drugmakers told hospitals they might experience delays in deliveries of saline.
Read the whole story on our sister site, Drug Delivery Business News
The post Baxter cleared from DoJ antitrust saline probe appeared first on MassDevice.